Hamlet Pharma enters into Patent Licensing Agreement
A patent licensing agreement has been signed between Hamlet Pharma AB and Linnane Pharma AB to secure the development and commercialisation of BAMLET for use other than as a pharmaceutical.
Today, Hamlet Pharma AB has signed a patent licensing agreement with Linnane Pharma AB for the development of BAMLET; a complex formed by bovine alpha-lactalbumin and oleic acid. Hamlet Pharma AB retains the rights to develop BAMLET as a pharmaceutical but licenses to Linnane Pharma AB the rights to develop BAMLET for other, non-pharmaceutical purposes. The agreement stipulates that Linnane Pharma AB will pay an annual royalty of 10% of its gross income to Hamlet Pharma AB as long as patents protecting the use of BAMLET are valid. The patent licensing agreement supports Hamlet Pharma’s strategy to focus solely on the development of drugs against various cancer types.
Linnane Pharma AB, through its unique knowledge of the science behind BAMLET, its applications, production and product profiling, is well positioned to effectively pursue the development and commercialization of BAMLET's non-pharmaceutical potential. This solution will allow Hamlet Pharma AB to focus on the clinical development of its drug candidate Alpha1H.
The chairman of the board did not participate in Hamlet Pharma’s decision to enter into this agreement.
For more information, please contact
Catharina Svanborg, Chairperson of the board, Hamlet Pharma, +46 709 42 65 49
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo.
This information is insider information that Hamlet Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact persons set out above, on May 12, 2020.